Asabys Reaches 180 Million Euros after Closing its New Fund with Sabadell

Asabys Partners has announced the closing of its second fund, Sabadell Asabys Health Innovation Investments II (Sahii II), with total commitments of €180 million, exceeding its initial target of €150 million .

Sahii II brings in new US and international investors, and once again has the strategic support of the main investor, Banco Sabadell, plus the European Investment Fund, FondICO Global, Innvierte Economía Sostenible and the Institut Català de Finances (ICF), among others.

Sahii II will invest in twelve to fifteen companies in line with Asabys’ core strategy of funding biopharma, medical device and digital health companies developing innovative solutions for unmet medical needs.

Asabys Partners has raised nearly 300 million since its founding in 2018

The first closing of the Sahii II fund was announced in January 2023 and it has since invested in five companies: Deepull, Orikine Bio, Gradient Denervation Technologies, Allox and Augustine Therapeutics .

“We value the trust of our new and existing investors, who have supported us with this second fund and share our commitment to global innovation in life sciences and emerging scientific developments in artificial intelligence (AI), biology and new materials; the team’s experience and the track record we have built since our founding in 2018 provide us with a solid position to continue executing our investment strategy,” commented Josep Sanfeliu, founding partner and manager of Asabys.

“The successful and oversubscribed closing of our Sahii II fund allows us to continue investing in the life sciences ecosystem in Spain, while strategically expanding our focus to Europe and other global markets; this new fund will allow us to support highly differentiated companies driven by science and technology, which develop new products that provide real benefits for patients,” added Clara Campàs, founding partner and manager of Asabys.

Since its founding in 2018, Asabys has raised nearly €300 million in assets under management , invested in seventeen companies, with three divestments to date. The team is made up of eleven professionals with extensive scientific and technical experience, as well as years of experience investing in the industry, backed by a group of venture capital partners and advisors.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us